Lipid Dysregulation in Sepsis: A Prognostic Marker for Mortality and Organ Dysfunction

BACKGROUND: Sepsis is a life-threatening condition characterized by systemic inflammation and organ dysfunction, with significant morbidity and mortality rates. Alterations in lipid metabolism, particularly reductions in cholesterol, HDL, and LDL levels, are increasingly recognized as key indicators of sepsis severity and prognosis.(1,2) OBJECTIVES: This study aimed to compare lipid profiles of critically ill patients with sepsis and non-infective SIRS, assess the correlation of lipid changes with 30-day mortality, and evaluate their association with organ dysfunction using the Sequential Organ Failure Assessment (SOFA) score to explore their prognostic value in critical care settings.(3,4) METHODS: This prospective observational study was conducted over 12 months in the critical care unit of a tertiary care hospital in New Delhi. A total of 163 critically ill patients, including 111 with sepsis and 52 with non-infective systemic inflammatory response syndrome (SIRS), were enrolled. Lipid profiles, comprising total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, and very-low-density lipoprotein (VLDL), were measured on Day 0 (admission) and Day 3. Clinical parameters, SOFA scores, and 30-day mortality data were recorded. Statistical analyses included independent t-tests, Pearson correlation coefficients, and linear regression to evaluate associations between lipid parameters, organ dysfunction, and outcomes.(5,6) RESULTS: The study demonstrated significant alterations in lipid profiles among critically ill patients with sepsis compared to those with non-infective systemic inflammatory response syndrome (SIRS). Sepsis patients exhibited markedly lower cholesterol levels at baseline (mean: 108.94 mg/dL) compared to non-sepsis patients (mean: 162.61 mg/dL, p < 0.0001). By Day 3, cholesterol levels declined further in sepsis patients (mean: 107.76 mg/dL) compared to non-sepsis patients (mean: 141.15 mg/dL, p < 0.0001). HDL levels were significantly reduced in sepsis patients at baseline (mean: 27.6 mg/dL) compared to non-sepsis patients (mean: 39.8 mg/dL, p < 0.0001) and dropped further by Day 3 (mean: 22.8 mg/dL vs. 34.4 mg/dL, p < 0.0001). LDL levels showed a similar pattern, with sepsis patients having lower levels at baseline (mean: 66.0 mg/dL) compared to non-sepsis patients (mean: 89.4 mg/dL, p < 0.0001) and continuing to decline by Day 3 (mean: 68.3 mg/dL vs. 85.4 mg/dL, p = 0.0025). TG and VLDL levels showed no statistically significant differences between the groups. Cholesterol, HDL, and LDL levels showed negative correlations with 30-day mortality (p <0.05). A similar trend was observed with SOFA scores, underscoring the prognostic value of lipid profiles in sepsis.(7) DISCUSSION: This study highlights significant lipid dysregulation in sepsis, with marked reductions in cholesterol, HDL, and LDL levels strongly linked to disease severity (SOFA scores) and 30-day mortality. These findings underscore their potential as cost-effective biomarkers for identifying high-risk patients and guiding treatment. The role of lipid metabolism in immune modulation and endotoxin neutralization suggests therapeutic possibilities, such as HDL-mimetic therapies or lipid supplementation, to mitigate inflammation and improve outcomes. Further research is essential to confirm these findings, establish lipid thresholds, and evaluate targeted therapies, paving the way for personalized treatment strategies to enhance sepsis survival.